Suzanne Pickering

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/3711270/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Combined epidemiological and genomic analysis of nosocomial SARS-CoV-2 infection early in the pandemic and the role of unidentified cases in transmission. Clinical Microbiology and Infection, 2022, 28, 93-100.	2.8	21
2	Disrupted Peyer's Patch Microanatomy in COVID-19 Including Germinal Centre Atrophy Independent of Local Virus. Frontiers in Immunology, 2022, 13, 838328.	2.2	9
3	ChAdOx1 nCoV-19 vaccine elicits monoclonal antibodies with cross-neutralizing activity against SARS-CoV-2 viral variants. Cell Reports, 2022, 39, 110757.	2.9	10
4	Clinical utility of targeted SARS-CoV-2 serology testing to aid the diagnosis and management of suspected missed, late or post-COVID-19 infection syndromes: Results from a pilot service implemented during the first pandemic wave. PLoS ONE, 2021, 16, e0249791.	1.1	6
5	The Polybasic Cleavage Site in SARS-CoV-2 Spike Modulates Viral Sensitivity to Type I Interferon and IFITM2. Journal of Virology, 2021, 95, .	1.5	121
6	More than the Eye Can See: Shedding New Light on SARS-CoV-2 Lateral Flow Device-Based Immunoassays. ACS Applied Materials & Interfaces, 2021, 13, 25694-25700.	4.0	10
7	Neutralization potency of monoclonal antibodies recognizing dominant and subdominant epitopes on SARS-CoV-2 Spike is impacted by the B.1.1.7 variant. Immunity, 2021, 54, 1276-1289.e6.	6.6	112
8	Comparative performance of SARS-CoV-2 lateral flow antigen tests and association with detection of infectious virus in clinical specimens: a single-centre laboratory evaluation study. Lancet Microbe, The, 2021, 2, e461-e471.	3.4	109
9	Neutralizing antibody activity in convalescent sera from infection in humans with SARS-CoV-2 and variants of concern. Nature Microbiology, 2021, 6, 1433-1442.	5.9	94
10	Longitudinal observation and decline of neutralizing antibody responses in the three months following SARS-CoV-2 infection in humans. Nature Microbiology, 2020, 5, 1598-1607.	5.9	1,115
11	Comparative assessment of multiple COVID-19 serological technologies supports continued evaluation of point-of-care lateral flow assays in hospital and community healthcare settings. PLoS Pathogens, 2020, 16, e1008817.	2.1	105
12	Real-world evaluation of a novel technology for quantitative simultaneous antibody detection against multiple SARS-CoV-2 antigens in a cohort of patients presenting with COVID-19 syndrome. Analyst, The, 2020, 145, 5638-5646.	1.7	26
13	HIV-1 Vpu Downregulates Tim-3 from the Surface of Infected CD4 ⁺ T Cells. Journal of Virology, 2020, 94, .	1.5	28
14	Upregulation of BST-2 by Type I Interferons Reduces the Capacity of Vpu To Protect HIV-1-Infected Cells from NK Cell Responses. MBio, 2019, 10, .	1.8	16
15	HLA-C downregulation by HIV-1 adapts to host HLA genotype. PLoS Pathogens, 2018, 14, e1007257.	2.1	30
16	Inhibiting the Ins and Outs of HIV Replication: Cell-Intrinsic Antiretroviral Restrictions at the Plasma Membrane. Frontiers in Immunology, 2017, 8, 1853.	2.2	21
17	HIV-1 Vpu Mediates HLA-C Downregulation. Cell Host and Microbe, 2016, 19, 686-695.	5.1	127
18	Serine Phosphorylation of HIV-1 Vpu and Its Binding to Tetherin Regulates Interaction with Clathrin Adaptors. PLoS Pathogens, 2015, 11, e1005141.	2.1	58

#	Article	IF	CITATIONS
19	Preservation of Tetherin and CD4 Counter-Activities in Circulating Vpu Alleles despite Extensive Sequence Variation within HIV-1 Infected Individuals. PLoS Pathogens, 2014, 10, e1003895.	2.1	54
20	Retroviral Retention Activates a Syk-Dependent HemITAM in Human Tetherin. Cell Host and Microbe, 2014, 16, 291-303.	5.1	54
21	Innate Sensing of HIV-1 Assembly by Tetherin Induces NFκB-Dependent Proinflammatory Responses. Cell Host and Microbe, 2012, 12, 633-644.	5.1	251